PMS and Cyclical Breast Pain

This is chasteberry's home ground. If you strip away everything the supplement aisle claims for Vitex agnus-castus and keep only what has been tested in double-blind, placebo-controlled trials, two uses survive in reasonable shape: premenstrual syndrome and cyclical breast pain. They are not two separate findings. Breast tenderness is one of the PMS symptoms that improves most consistently, and both trace back to the same lever — a gentle downward nudge on prolactin during the second half of the cycle.

What follows is the trial evidence in detail: who was studied, which extract, at what dose, for how long, and what the numbers were — including the trials where the effect faded, the reviewers who think the pooled effect is inflated, and the study that reported a 50 percent placebo response. A herb can be genuinely useful and the literature about it can still be flawed. Both are true here.

Table of Contents

  1. What PMS Is, and How It Is Diagnosed
  2. The Landmark BMJ Trial
  3. The Chinese Trials: BNO 1095
  4. Finding the Dose: The Ze 440 Dose-Ranging Study
  5. The Rest of the PMS Trial Set
  6. What the Meta-Analyses Conclude — Including the Awkward Part
  7. Cyclical Breast Pain: The Clearest Mechanistic Fit
  8. Chasteberry Versus the Alternatives
  9. PMDD: Where the Evidence Thins
  10. How to Give It a Fair Trial
  11. When Not to Reach for It
  12. Key Research Papers
  13. Connections

What PMS Is, and How It Is Diagnosed

Premenstrual syndrome is a pattern, not a symptom. The defining feature is timing: physical and emotional symptoms appear in the luteal phase — the roughly two weeks between ovulation and the period — and clear within a few days of bleeding starting. The symptom list is long and varies between people: irritability, low or swinging mood, anger, tearfulness, anxiety, headache, breast fullness and tenderness, bloating and fluid retention, food cravings, fatigue, disturbed sleep, acne.

Most menstruating people notice something premenstrually. The clinically meaningful group is smaller: reviews put the proportion with severe PMS at roughly 5 to 8 percent. Above that sits premenstrual dysphoric disorder (PMDD), a formal psychiatric diagnosis dominated by mood symptoms severe enough to damage work and relationships.

One practical point before any treatment: the diagnosis is made prospectively, with a diary. Two months of daily symptom ratings is the standard, and it exists because retrospective recall is unreliable — people reliably over-attribute symptoms to the premenstrual window. This matters for chasteberry specifically. Every serious trial ran a screening and baseline phase of two or three cycles before randomisation, precisely so that the people enrolled genuinely had a cyclical pattern. If you skip that step at home, you are treating something you have not confirmed, and you will have no reliable way to judge whether the herb worked.

The trials also used validated instruments rather than "do you feel better?" — the Moos Menstrual Distress Questionnaire, the Premenstrual Tension Syndrome scale, the PMS Diary, and visual analogue scales for individual symptoms. A simple home version is a daily 0–10 rating of your two or three worst symptoms, kept for two cycles before starting anything.

The Landmark BMJ Trial

The study that put chasteberry on the map appeared in the BMJ in January 2001. It is worth knowing in detail, because almost every claim made for chasteberry ultimately leans on it.

Read the responder figures the way a clinician would. A 52-versus-24-percent split is a difference of 28 percentage points, which corresponds to roughly one additional responder for every three to four women treated. That is a respectable number for a well-tolerated over-the-counter agent, and it is nowhere near "everybody gets better." Roughly half the women on chasteberry did not meet the responder threshold.

The limitations are equally worth naming. The trial ran three cycles, so nothing is known from it about longer use. Symptom self-report is the outcome, with no biochemical endpoint. And the trial was conducted by an investigator with an established relationship to the extract's manufacturer — a pattern that recurs across this literature and that the later meta-analysts flag explicitly.

The Chinese Trials: BNO 1095

The second pillar comes from Peking Union Medical College Hospital and uses a different standardised extract, BNO 1095, corresponding to 40 mg of herbal drug per tablet.

He and colleagues, Maturitas 2009. A prospective, double-blind, placebo-controlled, multi-centre trial in Chinese women with moderate to severe PMS. After a three-cycle screening and preparation phase, 217 women were randomised — 108 active, 109 placebo — and treated for up to three cycles. Efficacy used a Chinese-language PMS Diary (PMSD) and the PMTS scale. Mean total PMSD score fell from 29.23 to 6.41 on chasteberry and from 28.14 to 12.64 on placebo. The change was significantly larger with chasteberry (22.71 ± 10.33 versus 15.50 ± 12.94, p < 0.0001). No serious adverse events occurred in either group.

Now the detail that most write-ups quietly drop: the authors state plainly that a placebo effect of 50 percent was found in the present study. Placebo scores fell by more than half. That is not a flaw in the trial — it is a fact about PMS, which is a subjective, fluctuating, expectation-sensitive condition with a strong tendency to improve when someone is paying structured attention to it. It means two things. Uncontrolled testimonials about chasteberry are close to worthless as evidence. And the real, attributable benefit is the gap between the two curves, not the size of the fall you personally experience.

Ma and colleagues, Gynecological Endocrinology 2010. A smaller companion study, 67 women randomised to one BNO 1095 tablet daily or placebo, scored across four symptom factors: negative affect, water retention, food cravings, and pain. PMSD sum score fell from 29.38 ± 7.63 to 4.28 ± 5.76 on chasteberry versus 28.76 ± 8.23 to 11.79 ± 11.78 on placebo. The between-group difference reached significance for the sum score and for negative affect and water retention specifically — but not for food cravings or pain. That symptom-level breakdown is more informative than a global score: it suggests the mood and fluid-retention components respond better than cravings and pain do.

Finding the Dose: The Ze 440 Dose-Ranging Study

Most herbal doses are inherited from tradition or set by whatever the manufacturer chose. Chasteberry is one of the few with an actual dose-finding trial, published in Phytomedicine in 2012.

162 women aged 18–45 with PMS were randomised in a multicentre, double-blind, placebo-controlled, parallel-group design to placebo, 8 mg, 20 mg or 30 mg of Ze 440 over three menstrual cycles. Severity was scored on visual analogue scales for irritability, mood alteration, anger, headache, bloating and breast fullness.

The result was clean, and unusually so:

This is the single most useful practical finding in the chasteberry literature, and it cuts both ways. It tells you that a product delivering a Ze 440-equivalent 20 mg has a tested rationale, and that a low-dose product may genuinely do nothing. It also tells you that taking more buys nothing — the dose-response plateaus, so doubling up is spending money for no additional effect.

The Rest of the PMS Trial Set

Beyond the four headline trials, a handful of studies fill in the picture. Their designs are weaker, and they are worth reading with that in mind.

Berger and colleagues, Archives of Gynecology and Obstetrics 2000. A prospective multicentre trial of Ze 440 (20 mg native extract) in 50 women, 43 completing an eight-cycle protocol: two baseline, three treatment, three post-treatment. Moos MDQ score fell 42.5 percent (p < 0.001), and 20 of 43 met the 50-percent responder threshold. Two details make this study unusually informative. First, symptoms gradually returned after treatment stopped — but a 20 percent improvement over baseline persisted three cycles later, which is what you would expect from an agent that shifts a set-point rather than masking symptoms. Second, 13 of the 43 women were taking oral contraceptives concurrently, and no difference in response was seen between those on and off the pill. That is the closest thing to interaction data anyone has, and it is reassuring rather than conclusive. Note also that resting blood prolactin stayed within the physiological range throughout — chasteberry did not crash it.

Loch and colleagues, Journal of Women's Health and Gender-Based Medicine 2000. A very large post-marketing observation — 1,634 women — but an open study without a control group, which is why the impressive-sounding numbers (93 percent reporting fewer or no symptoms after three cycles) carry so little weight. With a documented 50 percent placebo response in this condition, an uncontrolled 93 percent tells you almost nothing about the drug. Its genuine value is as a safety dataset: adverse drug reactions were suspected in 1.2 percent, none serious.

Momoeda and colleagues, Advances in Therapy 2014. A multicentre, prospective, open-label single-arm phase 3 study in 69 Japanese women given 20 mg chasteberry extract daily for three cycles. Again uncontrolled, so the 91 percent responder rate at cycle three should be read as "response," not "drug effect." Its useful contribution is the time course: the total VAS score dropped significantly after the first cycle and continued to fall through cycles two and three, with the responder rate climbing steadily. Some benefit arrives early; most accumulates.

Zamani and colleagues, Acta Medica Iranica 2012. A randomised, placebo-controlled, double-blind study in 128 Iranian women that is interesting mainly because it broke the usual protocol: 40 drops of chasteberry extract given for only six days before menses, over six cycles, rather than continuously. It reported significant benefit over placebo. This is the one published hint that intermittent luteal-phase dosing might work, and it stands alone against a body of continuous-dosing trials — interesting, not established.

Ambrosini and colleagues, Acta Neurologica Belgica 2013. An open-label observation in migrainous women with PMS, reporting reduced attack frequency. Open-label and small; a hypothesis, not a finding.

What the Meta-Analyses Conclude — Including the Awkward Part

Three systematic reviews have pooled this literature, and reading them side by side is more instructive than reading any one.

van Die and colleagues (Planta Medica, 2013) identified 13 randomised controlled trials and included 12: eight in PMS, two in PMDD, two in latent hyperprolactinaemia. For PMS, seven of eight trials found chasteberry superior — to placebo in five of six, to pyridoxine in one, to magnesium oxide in one. Methodological quality was rated moderate to high, adverse events mild and infrequent. This is the most favourable of the three reviews.

Verkaik and colleagues (American Journal of Obstetrics and Gynecology, 2017) found 17 randomised trials and pooled 14. Thirteen of 14 reported positive effects, and the pooled effect was large — Hedges g of −1.21 (95 percent CI −1.53 to −0.88). And then the authors did something unusual and admirable: they told readers not to believe their own headline number. Heterogeneity was 91 percent — the trials disagree with each other far more than chance allows, and the reviewers could not identify what explained it. Funnel plots and Egger tests suggested publication bias. Most trials carried a high risk of bias. Their conclusion states that the pooled effect should be treated as "merely explorative and, at best, overestimating the real treatment effect."

Csupor and colleagues (Complementary Therapies in Medicine, 2019) took the strictest approach: they applied the CONSORT extension for herbal interventions, which requires a trial to describe its preparation well enough that the result can be attributed to something specific. Out of 21 clinical trials, only three met the bar — the rest could not be used as evidence of efficacy because of incomplete reporting, especially of the medication itself. Those three trials (520 women, all using Ze 440 or BNO 1095) gave a relative risk of remission of 2.57 (95 percent CI 1.52–4.35): women on chasteberry were about two and a half times as likely to remit as women on placebo.

Put those together and a fair verdict emerges. The direction of effect is consistent and the best-characterised extracts do beat placebo. The magnitude is uncertain and probably smaller than the pooled figures suggest. And the reason for the uncertainty is not that chasteberry is mysterious — it is that most trials of it were reported too poorly to count, and the field is entangled with the two manufacturers whose extracts it studies.

Cyclical Breast Pain: The Clearest Mechanistic Fit

Cyclical mastalgia is bilateral, diffuse, premenstrual breast pain that cannot be localised to one spot — it builds through the luteal phase and eases with menstruation. It is common, benign, and genuinely miserable. And it is the use where chasteberry's mechanism makes the most sense: breast tissue responds directly to prolactin, and cyclical mastalgia has long been linked to latent hyperprolactinaemia, in which resting prolactin is normal but the pituitary over-responds to stimulation because dopamine's brake is weak.

The Halaska trial (The Breast, 1999) is the placebo-controlled anchor. Women with mastalgia on at least five days in the pre-treatment cycle took a chasteberry solution, 2 × 30 drops daily, for three cycles, rating pain once per cycle on a visual analogue scale. Mean pain reduction was 21.4 mm after one cycle and 33.7 mm after two with chasteberry (n = 48), versus 10.6 mm and 20.3 mm with placebo (n = 49) — significant at both points (p = 0.018 and p = 0.006). Then the honest part, which secondary sources routinely omit: after three cycles the difference was only of borderline significance (34.3 mm versus 25.7 mm, p = 0.064), because the placebo group kept improving. Adverse events were equal in both arms.

The 2020 meta-analysis (Ooi and colleagues, Journal of Women's Health) is the best single summary. It reviewed 25 studies — 17 randomised, eight not — and found chasteberry effective at relieving breast pain intensity and at lowering raised serum prolactin in women of reproductive age, with or without accompanying PMS. Typical dosing across the literature was 20–40 mg/day for three months. A deliberately conservative meta-analysis restricted to six studies (n = 718; 356 chasteberry, 362 placebo) produced a moderate effect size, SMD 0.67 (95 percent CI 0.5–0.85), favouring chasteberry. Seven trials found it non-inferior to pharmaceutical comparators — dopamine agonists, NSAIDs, serotonin reuptake inhibitors and hormonal contraceptives. Adverse events were mild and reversible. The reviewers still noted that risk of bias was unclear in most included studies because of insufficient reporting.

A moderate effect size of 0.67 is, in plain terms, a difference you would notice but not a transformation. For a condition where the alternatives are NSAIDs, hormonal manipulation or bromocriptine — each with its own burden — a well-tolerated agent with a moderate effect is a reasonable first move.

Chasteberry Versus the Alternatives

Head-to-head studies are more useful than placebo comparisons for deciding what to actually do. Four are worth knowing.

PMDD: Where the Evidence Thins

Premenstrual dysphoric disorder is not severe PMS by another name — it is a distinct diagnosis in DSM-5, dominated by mood symptoms (marked irritability, depressed mood, anxiety, affective lability) severe enough to interfere with functioning. Its best-established treatments are SSRIs, which for PMDD often work within days rather than weeks and can be dosed only in the luteal phase.

Two trials speak to chasteberry here, and they disagree. Atmaca and colleagues (Human Psychopharmacology, 2003) recruited 41 women with DSM-IV PMDD after a two-month screening period and randomised them to fluoxetine or chasteberry extract for two months of single-blind, rater-blinded treatment. Response rates were similar — 68.4 percent on fluoxetine (13 of 19), 57.9 percent on chasteberry (11 of 19) — with no statistically significant difference. But the authors added a genuinely useful observation: fluoxetine was more effective for the psychological symptoms, while chasteberry did more for the physical ones. The second PMDD trial catalogued in the van Die review reported fluoxetine outperforming chasteberry.

Read those honestly and the conclusion is: chasteberry is not a demonstrated treatment for PMDD. Two small trials, one single-blind, split verdict, and a signal that the herb's action sits on the physical rather than the mood side — which is exactly the wrong half for a mood-dominated diagnosis. If premenstrual symptoms are severe enough to threaten your job, your relationships or your safety, that is a conversation with a clinician about SSRIs or hormonal suppression, not a supplement decision. Chasteberry may still be a reasonable adjunct for the bloating and breast pain that ride along with PMDD, but the mood component needs proper treatment.

How to Give It a Fair Trial

If the pattern fits — cyclical, luteal-phase symptoms with breast tenderness prominent — here is how the trial evidence translates into a home protocol.

  1. Keep a baseline diary for two cycles first. Daily 0–10 ratings of your worst two or three symptoms. Without this you cannot distinguish a real effect from a good month.
  2. Pick a product with a real dose. A Ze 440-equivalent 20 mg, or a BNO 1095 tablet, or a standardised extract stating milligrams per capsule. See Forms, Dosing and Interactions for how to read a label. The 8 mg arm of the dose-ranging trial failed, which is what an under-dosed product looks like.
  3. Take it once daily, in the morning, every day of the cycle. That is what the trials did. Prolactin has a strong overnight rhythm, which is the usual rationale for morning dosing.
  4. Give it three full cycles. Expect partial improvement after one and the bulk of it by three.
  5. Judge it against your diary, not your memory. Compare the luteal-phase averages of cycles four and five against cycles one and two.
  6. If three cycles produce nothing, stop. The evidence does not support the idea that a longer run rescues a non-response.
  7. Expect symptoms to drift back if you stop. In the Berger study they returned gradually over three post-treatment cycles, though not all the way to baseline.

When Not to Reach for It

Some of these are safety issues and some are diagnostic ones. All of them are more important than the question of which brand to buy.

Key Research Papers

Every identifier below was verified live against NCBI E-utilities before it was written; author, title, journal and year all had to match.

Placebo-controlled PMS trials

  1. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322(7279):134–137. 170 women evaluated; responder rates 52 percent versus 24 percent over three cycles.
  2. He Z, Chen R, Zhou Y, et al. Treatment for premenstrual syndrome with Vitex agnus castus: a prospective, randomized, multi-center placebo controlled study in China. Maturitas. 2009;63(1):99–103. 217 women; PMSD 29.23 → 6.41 active versus 28.14 → 12.64 placebo; a 50 percent placebo effect reported.
  3. Ma L, Lin S, Chen R, Wang X. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecological Endocrinology. 2010;26(8):612–616. 67 women; significant for negative affect and water retention, not for cravings or pain.
  4. Schellenberg R, Zimmermann C, Drewe J, Hoexter G, Zahner C. Dose-dependent efficacy of the Vitex agnus castus extract Ze 440 in patients suffering from premenstrual syndrome. Phytomedicine. 2012;19(14):1325–1331. 162 women; 8 mg failed, 20 mg worked, 30 mg added nothing.
  5. Zamani M, Neghab N, Torabian S. Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome. Acta Medica Iranica. 2012;50(2):101–106. 128 women; the unusual six-days-premenstrually dosing schedule over six cycles.

Uncontrolled and open-label PMS studies

  1. Berger D, Schaffner W, Schrader E, Meier B, Brattström A. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Archives of Gynecology and Obstetrics. 2000;264(3):150–153. 43 completers over eight cycles; symptoms returned gradually after stopping; no difference between women on and off oral contraceptives; resting prolactin stayed physiological.
  2. Momoeda M, Sasaki H, Tagashira E, Ogishima M, Takano Y, Ochiai K. Efficacy and safety of Vitex agnus-castus extract for treatment of premenstrual syndrome in Japanese patients: a prospective, open-label study. Advances in Therapy. 2014;31(3):362–373. 69 women, 20 mg daily; the clearest description of the response time course.
  3. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. Journal of Women's Health and Gender-Based Medicine. 2000;9(3):315–320. 1,634 women but no control group — a safety dataset, not efficacy evidence.
  4. Ambrosini A, Di Lorenzo C, Coppola G, Pierelli F. Use of Vitex agnus-castus in migrainous women with premenstrual syndrome: an open-label clinical observation. Acta Neurologica Belgica. 2013;113(1):25–29.

Cyclical mastalgia

  1. Ooi SL, Watts S, McClean R, Pak SC. Vitex agnus-castus for the treatment of cyclic mastalgia: a systematic review and meta-analysis. Journal of Women's Health. 2020;29(2):262–278. 25 studies; conservative meta-analysis of six (n = 718) gave SMD 0.67 (95 percent CI 0.5–0.85).
  2. Halaska M, Beles P, Gorkow C, Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. The Breast. 1999;8(4):175–181. Significant at cycles one and two; borderline (p = 0.064) at cycle three.
  3. Dinç T, Coşkun F. Comparison of fructus agni casti and flurbiprofen in the treatment of cyclic mastalgia in premenopausal women. Ulusal Cerrahi Dergisi. 2014;30(1):34–38. 114 women; no significant difference between the herb and the NSAID.
  4. Mirghafourvand M, Mohammad-Alizadeh-Charandabi S, Ahmadpour P, Javadzadeh Y. Effects of Vitex agnus and flaxseed on cyclic mastalgia: a randomized controlled trial. Complementary Therapies in Medicine. 2016;24:90–95. 159 women in three arms; both actives beat placebo, neither beat the other.
  5. Kilicdag EB, Tarim E, Bagis T, et al. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. International Journal of Gynaecology and Obstetrics. 2004;85(3):292–293. A brief comparative report; limited reportable detail.

Systematic reviews, meta-analyses and PMDD

  1. Verkaik S, Kamperman AM, van Westrhenen R, Schulte PFJ. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology. 2017;217(2):150–166. Hedges g −1.21, heterogeneity 91 percent, evidence of publication bias; the authors call their own estimate explorative and probably inflated.
  2. Csupor D, Lantos T, Hegyi P, et al. Vitex agnus-castus in premenstrual syndrome: a meta-analysis of double-blind randomised controlled trials. Complementary Therapies in Medicine. 2019;47:102190. Only 3 of 21 trials met CONSORT herbal reporting standards; those three (520 women) gave RR 2.57 (95 percent CI 1.52–4.35).
  3. van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Medica. 2013;79(7):562–575. Seven of eight PMS trials positive; both PMDD trials described.
  4. Cerqueira RO, Frey BN, Leclerc E, Brietzke E. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Archives of Women's Mental Health. 2017;20(6):713–719.
  5. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Human Psychopharmacology. 2003;18(3):191–195. 41 women; response 68.4 percent fluoxetine versus 57.9 percent chasteberry; fluoxetine better for psychological symptoms, chasteberry for physical ones.

Live PubMed Searches

  1. Chasteberry and PMS
  2. Chasteberry and mastalgia
  3. Cyclical mastalgia randomised trials
  4. PMDD and luteal-phase SSRI dosing
  5. Ze 440 extract
  6. BNO 1095 extract
  7. Placebo response in PMS trials
  8. Prospective diaries for PMS diagnosis

Connections

Back to Table of Contents